Evidence map›Paper›PMID 40338451›Full record

ReviewPurinergic signalling2025

P2 receptors signaling in the esophagus: from inflammation to cancer.

Aline Zaparte, Fernanda F Cruz, Julia B de Souza, Fernanda B Morrone

Abstract readReview
In one paragraph

Review in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aline ZapartePrograma de Pós-Graduação Em Medicina E Ciências da Saúde, Pontifical Catholic University of RS, Avenida Ipiranga, 6690, 90619 - 900, Porto Alegre, RS, Brasil.
Fernanda F CruzPrograma de Pós-Graduação Em Biologia Celular E Molecular, Pontifical Catholic University of RS, Avenida Ipiranga, 6681, Partenon, 90619 - 900, Porto Alegre, RS, Brasil.
Julia B de SouzaPrograma de Pós-Graduação Em Medicina E Ciências da Saúde, Pontifical Catholic University of RS, Avenida Ipiranga, 6690, 90619 - 900, Porto Alegre, RS, Brasil.
Fernanda B MorronePrograma de Pós-Graduação Em Medicina E Ciências da Saúde, Pontifical Catholic University of RS, Avenida Ipiranga, 6690, 90619 - 900, Porto Alegre, RS, Brasil. fernanda.morrone@pucrs.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 314687/2021-1Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 24/2551-0001297-4
6 · The paper itself

Abstract

The signaling mechanisms of nucleotides and nucleosides have been extensively studied over the past decades in various conditions affecting distinct organs and tissues. It is well-established that purinergic receptors are expressed in healthy tissues, with expression levels often increasing under pathological conditions. These receptors play crucial roles in numerous physiological and pathological processes, including inflammation, tissue repair, and cellular signaling. However, the purinergic context in the esophagus and its associated pathologies remains poorly understood, representing a significant gap in current knowledge. In this review, we compiled and analyzed the available data on the involvement of P2 purinergic receptors in esophageal diseases, such as gastroesophageal reflux disease and esophageal carcinoma. Specifically, we discuss the pharmacological modulation, functional characterization, and expression patterns of these receptors in various esophageal cell lines and immune tissue samples, under both healthy and pathological conditions. Understanding the mechanisms of action and signaling pathways involving P2 purinergic receptors in the esophagus can offer valuable insights into their biological roles and emphasize their potential as therapeutic targets for future clinical applications.

Indexed as

Esophageal NeoplasmsEsophagusInflammationReceptors, Purinergic P2Signal TransductionAnimalsGastroesophageal RefluxHumansReceptors, Purinergic P2Esophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaGastroesophageal Reflux DiseaseImmunomodulationP2 receptorsP2X receptorsP2Y receptors

Identifiers

PMID40338451
PMCPMC12595161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.